PTC Stock Recent News

WARREN, N.J. , April 17, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2025 financial results and provide an update on the company's business and outlook on Tuesday, May 6, at 4:30 p.m.

PTC introduces Onshape AI Advisor and Onshape Government for designers, engineers, educators and professionals in regulated industries.

New AI-powered assistant offers designers step-by-step guidance and recommendations during design process Onshape Government delivers cloud-native CAD and PDM to aerospace and defense companies with ITAR and EAR compliance requirements BOSTON , April 15, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced two new offerings from its cloud-native Onshape® computer-aided design (CAD) and product data management (PDM) platform: Onshape AI Advisor, an intelligent, generative AI-powered assistant that enables the enhancement of design productivity and expertise, and Onshape Government, a specialized solution designed to meet the International Traffic in Arms Regulations (ITAR) and Export Administration Regulations (EAR) regulatory and compliance needs of U.S. government agencies and defense contractors. These offerings empower designers and engineers to work more efficiently, collaborate in real time, and deliver high-quality products to the market faster.

BOSTON , April 9, 2025 /PRNewswire/ -- PTC (Nasdaq: PTC) will release its fiscal 2025 second quarter results on Wednesday, April 30 th after the stock market closes. Senior management will host a live webcast and conference call to review the results on Wednesday, April 30 th at 5pm Eastern Time.

BOSTON , April 2, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced the acquisition of IncQuery Group. IncQuery Group offers application lifecycle management (ALM) and systems engineering development and consultancy services to global manufacturers and product companies.

WARREN, N.J. , March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 24, 2025, the company approved non-statutory stock options to purchase an aggregate of 12,000 shares of its common stock and 28,220 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 35 new employees.

PTC launches Codebeamer 3.0 to speed up product development, boost sustainability and ensure quality and compliance with full traceability and smarter tools.

PTC Therapeutics said on Friday the European Commission will remove its inherited progressive muscle-wasting disorder from the region after an advisory panel reaffirmed a negative opinion of the drug in January.

WARREN, N.J. , March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has adopted the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to not renew the authorization of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy.

Industry-leading ALM solution delivers enhanced speed and scalability with variant management Modern branching method and scaled working sets enable customers to accelerate development of products and ensure compliance Sustainability Template offers eco-friendly design best practices and reduces physical prototypes through reuse Provides end-to-end traceability and process support for product compliance in regulated industries BOSTON , March 27, 2025 /PRNewswire/ --  PTC (NASDAQ: PTC) today announced the release of its Codebeamer® 3.0 Application Lifecycle Management (ALM) solution, designed to enable companies to develop products faster, more sustainably, and with higher quality, as well as help ensure regulatory compliance. Faster: Codebeamer 3.0 introduces a modern branching method and scaled working sets that simplify collaboration between engineering teams and enable them to reduce overall development time.